ANDARINE – S4

Volume: 30 ML

Dosage: 25 MG/ML

Clinical dosing: 5 - 50 mg/day

Description:

Andarine (also marked as GTx-007 or S-4) is a oral, nonsteroidal, investigational Selective androgen receptor modulator, developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hyperplasia (BPH). It mimics many of the beneficial pharmacologic effects of testosterone. Andarine has chemical formula C19H18F3N3O6, molar mass 441.357 g·mol−1 and half-life about 200 minutes. A scientific study published in 2005 examined the effects of Andarine S-4 in the skeletal muscles, bones and pituitary glands of castrated male rats. 12 weeks after castration, animals were treated with Andarine (3 or 10 mg/kg), dihydrotestosterone (DHT) (3 mg/kg), or vehicle for 8 weeks. Andarine (doses 3 and 10 mg/kg) restored soleus muscle mass and strength and levator ani muscle mass to that seen in intact animals. Similar changes were also observed in DHT-treated (3 mg/kg) animals. Compared with the anabolic effects observed in muscle, DHT (3 mg/kg) stimulated prostate and seminal vesicle weights moire than 2-fold greater than that observed in intact controls, whereas Andarine (3 mg/kg) returned these androgenic organs to only 16 and 17%, respectively, of the control levels. Andarine (3 and 10 mg/kg) and DHT (3 mg/kg) restored castration-induced loss in lean body mass. Furthermore, Andarine treatment caused a significantly larger increase in total body bone mineral density than DHT. Andarine S-4 (3 and 10 mg/kg) also demonstrated agonist activity in the pituitary and significantly decreased plasma LH and FSH levels in castrated animals in a dose-dependent manner. In summary, the strong anabolic effects of Andarine S-4 in skeletal muscle, bone, and pituitary were achieved with minimal pharmacologic effect in the prostate.

Compound Specifications:

Originale product made in UK.